Dear Editor,Coronavirus disease 2019(COVID-19)is a highly infectious respiratory disease that continues to pose a serious global public health emergency.The disease shows a high infection rate,long incubation period,a...Dear Editor,Coronavirus disease 2019(COVID-19)is a highly infectious respiratory disease that continues to pose a serious global public health emergency.The disease shows a high infection rate,long incubation period,and rapidly emerging variants,which have led to its rapid spread worldwide(Krammer 2020).Many vaccines have been developed for the control of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),the virus responsible for COVID-19,including vaccines based on messenger RNA(mRNA)(Polack et al.2020),viral vectors(Zhu et al.2020),recombinant proteins(Yang et al.2020),and inactivated SARS-CoV-2(Zhang et al.2021).展开更多
SARS-CoV-2 infection is a global public health threat.Vaccines are considered amongst the most important tools to control the SARS-CoV-2 pandemic.As expected,deaths from SARS-CoV-2 infection have dropped dramatically ...SARS-CoV-2 infection is a global public health threat.Vaccines are considered amongst the most important tools to control the SARS-CoV-2 pandemic.As expected,deaths from SARS-CoV-2 infection have dropped dramatically with widespread vaccination.However,there are concerns over the duration of vaccine-induced protection,as well as their effectiveness against emerging variants of concern.Here,we constructed a recombinant chimpanzee adenovirus vectored vaccine expressing the full-length spike of SARS-CoV-2(Ad C68-S).Rapid and high levels of humoral and cellular immune responses were observed after immunization of C57BL/6J mice with one or two doses of Ad C68-S.Notably,neutralizing antibodies were observed up to at least six months after vaccination,without substantial decline.Single or double doses Ad C68-S immunization resulted in lower viral loads in lungs of mice against SARS-CoV-2 challenge both in the short term(21 days)and long-term(6 months).Histopathological examination of Ad C68-S immunized mice lungs showed mild histological abnormalities after SARS-CoV-2 infection.Taken together,this study demonstrates the efficacy and durability of the Ad C68-S vaccine and constitutes a promising candidate for clinical evaluation.展开更多
Dear Editor,COVID-19 caused by SARS-Co V-2,is still a big threat to human populations around the world.As of Jan 2022,over 292 million cases were reported worldwide with more than 5.4 million deaths.After it was first...Dear Editor,COVID-19 caused by SARS-Co V-2,is still a big threat to human populations around the world.As of Jan 2022,over 292 million cases were reported worldwide with more than 5.4 million deaths.After it was first reported in China in December 2019,the virus kept circulating and evolving and several variants with different transmissibility emerged in different countries and regions(WHO,2021a).展开更多
基金supported by Fudan University Special Funds for COVID-19the National Natural Science Foundation of China(32130063)+4 种基金the National Key Research and Development Program of China(2021YFE0201900 and 2021YFC2301700)China Postdoctoral Science Foundation(2020T130017ZX)the Starry Night Science Fund at Shanghai Institute for Advanced Study of Zhejiang University(SN-ZJU-SIAS-009)the STS Regional Key Project(KFJSTS-QYZD-2021-12-001)from Chinese Academy of SciencesHubei Science and Technology Major Project(2021ACB0004)。
基金supported by Strategic Priority Research Program of the Chinese Academy of Sciences(XDB39000000 to T.X.)National Natural Science Foundation of China(81925009 to T.X.,81790644 to T.X.,81900855 to M.Z.,82000941 to D.T.)+3 种基金Jack Ma Foundation(2019-nCoV)CAS Project for Young Scientists in Basic Research(YSBR-013)Fundamental Research Funds for the Central Universities(WK5290000001 to Y.C.,WK5290000002 to Y.Y.,WK2090050048 to M.Z.,WK2070000174 to M.Z.)supported by the Anhui Provincial Natural Science Foundation(1808085MH289 to M.Z.).Joint Laboratory of Innovation in Life Sciences from the University of Science and Technology of China(USTC)and Changchun Zhuoyi Biological Co.Ltd.
文摘Dear Editor,Coronavirus disease 2019(COVID-19)is a highly infectious respiratory disease that continues to pose a serious global public health emergency.The disease shows a high infection rate,long incubation period,and rapidly emerging variants,which have led to its rapid spread worldwide(Krammer 2020).Many vaccines have been developed for the control of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),the virus responsible for COVID-19,including vaccines based on messenger RNA(mRNA)(Polack et al.2020),viral vectors(Zhu et al.2020),recombinant proteins(Yang et al.2020),and inactivated SARS-CoV-2(Zhang et al.2021).
基金the National Natural Science Foundation of China(No.32070933 to J.M.Lan and Y.F.Yao)the Natural Science Foundation of Shanghai(No.20ZR1463900 to J.M.Lan)+3 种基金financially the STS regional key project(KFJ-STS-QYZD-2021-12-001 to Z.M.Yuan and C.Shan)from Chinese Academy of SciencesNational Key R&D Program of China 2021YFE0201900 to C.Shan and 2021YFC0863300 to Z.M.Yuan and C.Shanthe National Key R&D Program of China(No.2021YFC0863400)funding from Institut Pasteur,Fondation Merieux and the Chinese Academy of Sciences to G.W。
文摘SARS-CoV-2 infection is a global public health threat.Vaccines are considered amongst the most important tools to control the SARS-CoV-2 pandemic.As expected,deaths from SARS-CoV-2 infection have dropped dramatically with widespread vaccination.However,there are concerns over the duration of vaccine-induced protection,as well as their effectiveness against emerging variants of concern.Here,we constructed a recombinant chimpanzee adenovirus vectored vaccine expressing the full-length spike of SARS-CoV-2(Ad C68-S).Rapid and high levels of humoral and cellular immune responses were observed after immunization of C57BL/6J mice with one or two doses of Ad C68-S.Notably,neutralizing antibodies were observed up to at least six months after vaccination,without substantial decline.Single or double doses Ad C68-S immunization resulted in lower viral loads in lungs of mice against SARS-CoV-2 challenge both in the short term(21 days)and long-term(6 months).Histopathological examination of Ad C68-S immunized mice lungs showed mild histological abnormalities after SARS-CoV-2 infection.Taken together,this study demonstrates the efficacy and durability of the Ad C68-S vaccine and constitutes a promising candidate for clinical evaluation.
基金financially supported by the STS regional key project(KFJ-STSQYZD-2021-12-001 to Z.M.Y.and C.S.)from Chinese Academy of Sciencesthe National Key R&D Program of China(2021YFC0863300 to Z.M.Y.and C.S.)+1 种基金the National Key R&D Program of China(2021YFE0201900 to C.S.)the Science and Technology Major project of Hubei Province(2021ACB005 to C.S.and H.X.)。
文摘Dear Editor,COVID-19 caused by SARS-Co V-2,is still a big threat to human populations around the world.As of Jan 2022,over 292 million cases were reported worldwide with more than 5.4 million deaths.After it was first reported in China in December 2019,the virus kept circulating and evolving and several variants with different transmissibility emerged in different countries and regions(WHO,2021a).
